Subscribe
dna-istock-518143098-ralwel--2
ralwel / iStockphoto.com
14 December 2017Americas

Vertex and CRISPR Therapeutics to develop gene-editing treatment

US-based Vertex Pharmaceuticals and CRISPR Therapeutics have revealed plans to jointly develop and commercialise an investigational gene-editing treatment.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
FDA lifts hold on first human CRISPR trial
17 October 2018   The US Food and Drug Administration has allowed the first US-based human trial of CRISPR, the gene-editing technology, to proceed.
Americas
Vertex to buy diabetes biotech firm for $950m
4 September 2019   US-based Vertex Pharmaceuticals has announced it will pay $950 million to acquire Semma Therapeutics, a biotechnology company focused on researching a cure for Type 1 diabetes.
Biotechnology
Vertex signs $100m CRISPR deal to use sickle cell treatment
14 December 2023   Biotech firm agrees licence deal days after its gene editing treatment gets landmark FDA approval | Patents owned by the Broad Institute protect technology sold via Editas Medicines.


Editor's picks

Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024

Editor's picks

Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024

More on this story

Americas
FDA lifts hold on first human CRISPR trial
17 October 2018   The US Food and Drug Administration has allowed the first US-based human trial of CRISPR, the gene-editing technology, to proceed.
Americas
Vertex to buy diabetes biotech firm for $950m
4 September 2019   US-based Vertex Pharmaceuticals has announced it will pay $950 million to acquire Semma Therapeutics, a biotechnology company focused on researching a cure for Type 1 diabetes.
Biotechnology
Vertex signs $100m CRISPR deal to use sickle cell treatment
14 December 2023   Biotech firm agrees licence deal days after its gene editing treatment gets landmark FDA approval | Patents owned by the Broad Institute protect technology sold via Editas Medicines.

More on this story

Americas
FDA lifts hold on first human CRISPR trial
17 October 2018   The US Food and Drug Administration has allowed the first US-based human trial of CRISPR, the gene-editing technology, to proceed.
Americas
Vertex to buy diabetes biotech firm for $950m
4 September 2019   US-based Vertex Pharmaceuticals has announced it will pay $950 million to acquire Semma Therapeutics, a biotechnology company focused on researching a cure for Type 1 diabetes.
Biotechnology
Vertex signs $100m CRISPR deal to use sickle cell treatment
14 December 2023   Biotech firm agrees licence deal days after its gene editing treatment gets landmark FDA approval | Patents owned by the Broad Institute protect technology sold via Editas Medicines.

More features

Chinese biotech takes out US rival’s nucleic acid patent at PTAB
Lewis Roca promotes tech expert to managing partner
Panitch Schwarze brings in molecular biologist
US targets ‘product hopping’ with biologic litigation curbs
UPC confirms validity of Edwards Lifesciences heart valve tech patent
ITC concludes row over biotech lab equipment between US and German rivals
UKIPO launches ‘revolutionary’ patent filing and AI tool
USPTO clarifies AI's role in patent eligibility